An observational study in Peripheral Arterial Disease, Aortoiliac Occlusive Disease and Chronic Limb-Threatening Ischemia, sponsored by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Observational
Peripheral arterial disease involving the iliac arteries is a common manifestation of systemic atherosclerosis and a major cause of lifestyle-limiting claudication and chronic limb-threatening ischemia. Endovascular iliac artery stenting has become the preferred treatment strategy for most iliac lesions, including complex TransAtlantic Inter-Society Consensus II (TASC II) C and D lesions, owing to high technical success rates and lower perioperative morbidity compared with open surgical reconstruction.
Despite widespread adoption of endovascular treatment, available evidence regarding predictors of major adverse limb events (MALE) after iliac artery stenting remains limited, particularly in unselected real-world populations with substantial comorbidity burden. Patient-related factors, including frailty, may contribute to post-procedural outcomes in addition to lesion-related characteristics.
This retrospective single-center cohort study will evaluate clinical outcomes following endovascular iliac artery stenting in consecutive adult patients treated at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study will assess the occurrence of major adverse limb events (MALE), primary patency, peri-procedural complications, target lesion revascularization, restenosis or occlusion, and all-cause mortality. Clinical, anatomical, and procedural factors associated with adverse limb outcomes, including frailty assessed by the modified five-item Frailty Index (mFI-5), will also be investigated.
Peripheral arterial disease (PAD) involving the iliac arteries is a common manifestation of systemic atherosclerosis and represents a frequent cause of lifestyle-limiting intermittent claudication and chronic limb-threatening ischemia (CLTI). Over the past two decades, continuous advances in endovascular techniques, stent technology, and peri-procedural imaging have led to a progressive shift from open surgical reconstruction toward an endovascular-first strategy for the treatment of aortoiliac occlusive disease, including anatomically complex lesions classified as TransAtlantic Inter-Society Consensus II (TASC II) C and D.
Current international guidelines support endovascular treatment for most iliac lesions because of high technical success rates and lower perioperative morbidity compared with open surgical reconstruction. As a result, iliac artery stenting has become the predominant treatment modality in routine vascular practice. However, much of the available evidence is derived from selected patient populations or controlled clinical studies and may not fully reflect outcomes observed in unselected real-world cohorts with substantial comorbidity burden.
Although procedural success and vessel patency after iliac artery stenting have been widely reported, less information is available regarding predictors of clinically meaningful limb-related outcomes, particularly Major Adverse Limb Events (MALE). Furthermore, lesion morphology alone may not adequately explain variability in outcomes after technically successful revascularization. Patient-related factors, including frailty, chronic kidney disease, diabetes mellitus, coronary artery disease, and advanced age, may significantly influence post-procedural clinical trajectories. Frailty, assessed using the modified five-item Frailty Index (mFI-5), has been associated with adverse outcomes in cardiovascular and vascular surgical populations, but its prognostic role in patients undergoing iliac artery stenting remains insufficiently characterized.
This study is a single-center retrospective observational cohort study conducted at the Division of Vascular Surgery, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. Consecutive adult patients who underwent endovascular stenting for de novo stenotic or occlusive disease of the common and/or external iliac arteries between January 2023 and May 2025 will be included. Clinical, anatomical, procedural, and follow-up data will be retrospectively extracted from institutional vascular registries, imaging databases, and electronic medical records.
The primary objective is to evaluate MALE-free survival following endovascular iliac artery stenting. Secondary objectives include assessment of primary patency, peri-procedural complications, target lesion revascularization, restenosis or occlusion, and all-cause mortality. The study will also evaluate associations between baseline clinical and anatomical characteristics and adverse limb outcomes, with particular attention to frailty as assessed by the mFI-5.
Follow-up data are derived exclusively from routine clinical surveillance, including outpatient evaluations, ankle-brachial index measurements when available, duplex ultrasound examinations, and additional imaging studies performed according to clinical indications. Outcomes will be analyzed using Kaplan-Meier survival methods and Cox proportional hazards regression models to identify factors associated with adverse clinical outcomes after iliac artery stenting in a real-world population.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
This study's planned enrollment of 98 is below the median of 188 across 398 observational studies indexed under Peripheral Arterial Disease.
Browse Peripheral Arterial Disease studies →I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio is the lead sponsor of 160 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Consecutive adult patients (≥18 years), both male and female, undergoing endovascular stenting for stenotic or occlusive disease of the common and/or external iliac arteries (CIA/EIA) at IRCCS Galeazzi-Sant'Ambrogio, Milan, between January 2023 and May 2025, will be retrospectively included. Lesions will be classified according to TASC II, with an expected predominance (\~70%) of complex (C-D) lesions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients aged ≥18 years, of both male and female sex
Exclusion Criteria:
Primary open surgical revascularisation of the iliac axis (e.g., aorto- bifemoral bypass or endarterectomy).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
clinical assessment of symptoms, including intermittent claudication, rest pain, or wound status in patients with chronic limb-threatening ischemia (CLTI); physical examination with peripheral pulse assessment and, when available, ankle-brachial index (ABI) measurement; duplex ultrasound imaging of the treated iliac segment and downstream arterial circulation, performed according to institutional surveillance protocols or clinical indication; computed tomography angiography (CTA) or other cross-sectional imaging only in cases of suspected in-stent restenosis, occlusion, or clinical deterioration; documentation of clinically relevant adverse events, including Major Adverse Limb Events (MALE), reinterventions, amputations, and all- cause mortality, retrieved from outpatient records and the institutional electronic health record system.
Number of Participants Experiencing Major Adverse Limb Events (MALE) Within 12 Months
MALE is defined as a composite endpoint including: acute limb ischaemia requiring intervention, major amputation (above or below knee), or surgical/endovascular re-intervention on the target iliac vessel. Results will be reported as the number and proportion of participants experiencing at least one MALE event within 12 months of the index procedure. Independent predictors will be identified by multivariable Cox regression, including frailty (mFI-5), lesion complexity (TASC II class), stent type, and cardiovascular comorbidities.
Time frame: 12 months
Primary Patency of the Treated Iliac Artery Segment
Primary patency defined as freedom from target lesion revascularization and absence of documented iliac artery occlusion during follow-up, assessed by duplex ultrasound or cross-sectional imaging.
Time frame: 12 months
Number of Participants With Peri-Procedural Complications
Number of participants experiencing peri-procedural complications within 30 days after iliac stenting, including access-site complications, arterial dissection, perforation, pseudoaneurysm, hematoma formation, contrast-induced nephropathy, hemorrhagic events, and neurological events.
Time frame: 30 days
All-Cause Mortality
Number of participants who die from any cause following the index iliac stenting procedure.
Time frame: 12 months
Freedom From Target Lesion Revascularization (TLR)
Time from the index procedure to the first repeat endovascular or surgical intervention performed on the treated iliac artery segment
Time frame: 12 months
Number of Participants With Iliac Artery Restenosis or Occlusion
Number of participants with documented restenosis or occlusion of the treated iliac artery segment detected by duplex ultrasound, computed tomography angiography, or other clinically indicated imaging.
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio →